Kristeleit, R., Lisyanskaya, A., Fedenko, A., Dvorkin, M., de Melo, A., Shparyk, Y., Rakhmatullina, I., Bondarenko, I., Colombo, N., Svintsitskiy, V., Biela, L., Nechaeva, M., Lorusso, D., Scambia, G., Cibula, D.,
Póka, R., Oaknin, A., Safra, T., Mackowiak-Matejczyk, B., Ma, L., Thomas, D., Lin, K., McLachlan, K., Goble, S., Oza, A.:
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Lancet Oncol. 23 465-478, 2022.